Core Insights - PMGC Holdings Inc. has initiated strategic investments in fire prevention technology and the U.S. uranium energy market, highlighting its commitment to financing innovation in essential industries with significant growth potential [1][2] Investment Focus - The company believes there is a growing demand for sustainable energy solutions and innovative fire prevention technologies, with investments in uranium exploration supporting nuclear energy as a clean power source to reduce carbon emissions [2] - In the fire prevention sector, PMGC has invested in a U.S.-based company that is developing environmentally friendly technologies aimed at preventing fire ignition and spread, which could provide long-term solutions for saving lives and protecting real estate [3] Portfolio Management - PMGC is dedicated to keeping shareholders informed as its portfolio expands, with a commitment to report any individual investment that exceeds a 4.9% ownership threshold in compliance with SEC regulations [4] - PMGC Capital LLC operates as a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets, aiming to identify high-potential opportunities for sustainable growth and maximizing returns [5] Company Overview - PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries, currently comprising three wholly owned subsidiaries [6]

Core Insights - PMGC Holdings Inc. announced a research agreement with a leading preclinical CRO to evaluate EL-32, a novel engineered probiotic, for its potential in treating obesity [1][4] - The study will assess EL-32's effects on glycemic control and body composition in diet-induced obese mice, both as a monotherapy and in combination with semaglutide [1][5] - EL-32 targets myostatin and activin-A pathways, aiming to preserve muscle mass while reducing fat mass, addressing a critical need in obesity treatment [2][4][3] Company Overview - Northstrive Biosciences Inc., a subsidiary of PMGC Holdings, focuses on developing innovative solutions for obesity treatment, particularly through engineered probiotics [7] - The lead candidate, EL-32, is designed to work alongside existing GLP-1 receptor agonists, which have been shown to cause significant muscle mass loss during weight loss [2][3][4] - PMGC Holdings operates a diversified portfolio, including Northstrive Biosciences, PMGC Research, and PMGC Capital, aiming to maximize growth across various sectors [9]

New York, New York, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the completion of the previously announced warrant inducement with existing institutional investors for its client PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the "Company" or "PMGC") (NASDAQ:ELAB), a diversified holding company, for the exercise of certain outstanding Series A warran ...

Warrant Inducement Agreement - PMGC Holdings Inc has entered into a warrant inducement agreement with existing institutional investors for the exercise of certain outstanding Series A warrants [1] - The investors agreed to exercise the outstanding warrants to purchase 969,385 shares of the company's common stock at an amended exercise price of $2 00 [1] - The gross proceeds from the exercise of the warrants are expected to be approximately $1 9 million [1] - The closing of the warrant inducement transactions is expected to occur on or about January 28, 2025 [2] New Warrants Issuance - In consideration for the exercise of the warrants, the company agreed to issue new warrants to purchase an aggregate of 969,385 shares of common stock with an exercise price of $2 75 per share [3] - The new warrants are exercisable upon shareholder approval and will expire five years from the date of shareholder approval [3] - The company has agreed to file a registration statement within 30 days with the SEC covering the resale of the shares issuable upon exercise of the new warrants [3] Company Overview - PMGC Holdings Inc is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries [5] - The company's portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc, PMGC Research Inc, and PMGC Capital LLC [5]

Northstrive Biosciences Inc. was invited to present EL-22, a novel myostatin asset aimed at preserving muscle while on weight loss treatments, at the UCLA Obesity Symposium called Anti-Obesity Treatments: Challenges and Emerging Solutions, organized by UCLA Metabolism Theme. This is an invite only event that brings together industry leading voices in the obesity space.NEWPORT BEACH, Calif., Jan. 24, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: EL ...

NEWPORT BEACH, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the "Company" or "PMGC") (NASDAQ:ELAB) a diversified holding company today announced the closing of the previously announced divestiture of its 100% wholly owned subsidiary Elevai Skincare Inc. ("Elevai") pursuant to a definitive purchase agreement with Carmell Corporation ("Carmell") (the "Divestiture") and reaffirms its commitment to accelerating shareholder value creation and market leadership followi ...

Company Overview - PMGC Holdings Inc. has rebranded its subsidiaries to align with its evolving focus as a diversified holding company [1][3] - The company now manages three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [3] Subsidiary Details - PMGC Research Inc. (formerly Elevai Research Inc.) focuses on advancing scientific discovery through public-private collaborations and Canadian research grants [1][5] - Northstrive Biosciences Inc. (formerly Elevai Biosciences, Inc.) is dedicated to developing innovative aesthetic medicines, with its lead asset EL-22 targeting obesity by preserving muscle during weight loss treatments [2][5] Strategic Focus - Both subsidiaries aim to drive innovation and deliver transformative solutions in their respective fields [3]

Core Insights - PMGC Holdings Inc. has announced a strategic divestiture of its skincare subsidiary, Elevai Skincare, to enhance shareholder value and operational efficiency [1][2] - The sale is aimed at maximizing immediate financial benefits while positioning the company for future growth through structured royalties and milestone payments [2][4] - This divestiture aligns with PMGC's strategy to focus on transformative acquisitions that drive substantial growth and shareholder value [3][5] Financial and Operational Highlights - The divestiture has led to a reduction in cash burn by eliminating a loss-generating subsidiary, resulting in a leaner operational framework [4] - PMGC will receive approximately $1.1 million in stock from Carmell Corporation and retain a 5% royalty on skincare revenues over the next five years [4] - The company plans to redirect resources into high-potential assets, leveraging its expertise to create shareholder value [4][6] Strategic Vision - PMGC is committed to exploring accretive acquisitions and licensing opportunities in sectors with significant growth potential [7] - The company aims to identify undervalued assets that align with its vision of building a diversified and growth-oriented portfolio [7][9] - Current subsidiaries include Elevai Biosciences, Elevai Research, and PMGC Capital LLC, reflecting the company's focus on innovation and growth [10]

NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (NASDAQ:ELAB) (before and after the redomestication, the "Company" or "we") announced today that it completed a strategic reorganization. This reorganization included changing the Company's name from Elevai Labs Inc. to PMGC Holdings Inc. and redomiciling from Delaware to Nevada. Upon this reorganization, the Company will continue to trade on The Nasdaq Stock Market ("Nasdaq") under the ticker sy ...

Core Viewpoint - PMGC Holdings Inc. is undergoing a strategic reorganization to enhance operational efficiency and maximize shareholder value as a diversified holding company [1][3]. Group 1: Company Overview - PMGC Holdings Inc. (formerly Elevai Labs Inc.) is a diversified holding company managing a portfolio through strategic acquisitions and investments across various industries [2][3]. - The current portfolio includes four wholly owned subsidiaries: Elevai Skincare Inc., Elevai Biosciences Inc., Elevai Research Inc., and PMGC Capital LLC [2][12]. Group 2: Strategic Reorganization - The reorganization includes a name change to PMGC Holdings Inc. and a redomestication from Delaware to Nevada, effective December 20, 2024 [3][10]. - The company will continue trading on Nasdaq under the ticker symbol "ELAB" after the changes take effect on December 23, 2024 [3]. Group 3: Benefits of Redomiciling - Redomiciling to Nevada is aimed at streamlining operations and creating a more efficient legal and governance framework [4]. - Key benefits of redomiciling include a business-friendly regulatory environment, robust protections for directors and officers, cost efficiency through lower state franchise taxes, and flexibility in shareholder governance [11]. Group 4: Subsidiary Focus - Elevai Skincare Inc. specializes in physician-dispensed skincare solutions using proprietary technology [12]. - Elevai Biosciences Inc. focuses on biopharmaceutical advancements, including treatments for obesity and muscle preservation [12]. - Elevai Research Inc. conducts life sciences research supported by grants and partnerships [12]. - PMGC Capital LLC is a multi-strategy investment vehicle that seeks diversified opportunities across various markets, aiming for superior risk-adjusted returns [12].